Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Hold” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.25.

A number of research firms have recently issued reports on PYXS. Zacks Research downgraded shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Finally, Guggenheim boosted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, November 4th.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the period. Vanguard Group Inc. lifted its holdings in Pyxis Oncology by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Pyxis Oncology in the 2nd quarter valued at approximately $26,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Pyxis Oncology in the second quarter worth $37,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Pyxis Oncology during the third quarter worth $77,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Stock Down 4.4%

Shares of Pyxis Oncology stock opened at $4.37 on Thursday. The firm has a market cap of $272.08 million, a PE ratio of -2.73 and a beta of 1.41. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $4.85. The business’s fifty day simple moving average is $2.92 and its 200-day simple moving average is $1.79.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.